TO START A CELL LICENSING REQUEST – PLEASE FILL OUT REQUEST FORM

A NEUKOPANEL® OF NEUKOPLAST® NK-92 CELL LINES SUITABLE FOR A RANGE OF LABORATORY TESTING APPLICATIONS

ADCC ASSAYS – ROUTINE HASSLE
Brink Biologics, Inc. holds the exclusive non-clinical rights to the NK-92®️ cell line and its CD16 expressing derivatives, all of which are uniquely and ideally suited for antibody-dependent cell-mediated cytotoxicity (ADCC) assays.
ROUTINE ASSAY
TIME CONSUMING AND A LACK OF OPTIONS
OUR SIMPLE SOLUTION
The exclusive global provider of NK-92® cell line testing services, products, and sublicenses within the life sciences and device industry.
Highly published cell lines – over 200 publications.
Relevant Examples:
Schnueriger, A., et al. (2011). “Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.” Mol Immunol 48(12-13): 1512-1517.
Relevant Examples:
Schnueriger, A., et al. (2011). “Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.” Mol Immunol 48(12-13): 1512-1517.
NK-92® cells are the only continuously growing human NK cell adapted to mass production
Brink Biologics created the NK-92® master cell bank (MCB).
Brink Biologics created the NK-92® master cell bank (MCB).
NK-92® MCB has been accepted as clinical grade material by regulatory agencies across the world, including the US FDA, EMEA and Canada Health.
The sole holder of homogeneously pure NK-92® cell cultures with superb retention of phenotypic characteristics in more than 6 months of continuous culture.
Five Advantages of the Neukopanel® Cell Lines:
For the first time the means to establish a consistent, robust and reliable assay for assessment of true ADCC function.
Cost and Time Savings
True Cytotoxicity
Ease of Use
Robust Assay
Eliminates Phenotypic Variability
- Cost and time savings over common practice using donor-sourced (PBMC) NK cell isolation, expansion and maintenance in short term cultures
- Eliminates phenotypic variability of donor-sourced NK cells as Neukopanel cell lines offer clonal consistency, purity and reliability as an assay reagent
- Ease of use over donor-sourced NK cells and capable of long-term continuous cultures
- Ability to generate a readout spectrum with the use of our homozygous high and low affinity CD16 expressing lines alongside our negative control line for assay robustness
- True cytotoxicity rather than cell-binding readouts
Office
3530 John Hopkins Court
San Diego, CA 92121
Hours
8am to 5pm M-F
Call Us
Main: (858) 633-0300
Fax: (858) 380-1999
Email: info@brinkbiologics.com
©2015-2021 Brink Biologics, Inc. All Rights Reserved | Home | Platform | Privacy Policy | Legal Notice | Patent Notice
‘Brink Biologics’, ‘Taking You Beyond the Brink of Binding’, ‘Neukopanel’, ‘Killer Assays’ and ‘laNK’ are trademarks or registered trademarks of Brink Biologics, Inc., ‘haNK’, 'Neukoplast', and ‘NK-92’ are registered trademarks of Nantkwest, Inc.
The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.
The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.